Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Strategic Projects - Group

Université de Montréal

$91,000.00

ANR-Biocompatible poly(amphiphiles) to fold and stabilize engineered antibody fragments for in vivo molecular imaging in cancer.

EF 2013-14

Résumé
SUMMARY OF PROPOSAL FOR PUBLIC RELEASE (Use plain language.)Version française disponibleThe last decade has witnessed remarkable advances in the development of antibody drugs against moleculartargets. Engineered antibody fragments are among the most effective anti-cancer and anti-inflammatory drugson the market today. They are also the most expensive, carrying a cost upward from $ 50,000 a year perpatient. This cost places a heavy burden on the Canadian Health Care system and on the patient. It may comeas a surprise, that the stumbling block in this field is not the production of antibodies (there are more than 20on the market and hundreds in clinical trials), but rather the lack of robust injection formulations suitable todeliver fragile antibodies to the targeted site in vivo and able to resist rapid degradation upon storage or in theform of stock solutions. This project addresses these key issues by proposing means to employ finely designedamphiphilic macromolecules to rescue antibodies against loss of activity due to aggregation during refolding, tosolubilize them in their aqueous formulations until administration, and to prolong their lifetime in-vivo. Thesuccessful outcome of this project would remove one of the roadblocks towards availability of affordableantibody therapies and open up a new lucrative market to Supratek Pharma Inc., the industrial partner in thisapplication.The project brings together a Canadian academic laboratory that excels in the preparation of amphiphilicbiocompatible macromolecules, a Canadian company specializing in oncological drug delivery systems andtwo French laboratories, which are leaders in the biophysics of proteins/polymer complexes and the productionand of engineered antibody fragments for oncological therapies.
Programme
Strategic Projects - Group
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
396739-2010
Name nom
Winnik, Francoise
Department département
Pharmacie, faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2010
Award amount
91000
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1042
Committee name en
Strategic Projects Selection Panel - Biomedical Technologies
Committee name fr
Comité de sélection des projets stratégiques - Technologies biomédicales
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3750
Research subject group en
Polymer chemistry
Research subject group fr
Chimie des polymères
Research subject en
Polymer chemistry
Research subject fr
Chimie des polymères
Partie
3
Nb partie
3
Application title
ANR-Biocompatible poly(amphiphiles) to fold and stabilize engineered antibody fragments for in vivo molecular imaging in cancer.
Keyword
NSERC
Application summary
SUMMARY OF PROPOSAL FOR PUBLIC RELEASE (Use plain language.)Version française disponibleThe last decade has witnessed remarkable advances in the development of antibody drugs against moleculartargets. Engineered antibody fragments are among the most effective anti-cancer and anti-inflammatory drugson the market today. They are also the most expensive, carrying a cost upward from $ 50,000 a year perpatient. This cost places a heavy burden on the Canadian Health Care system and on the patient. It may comeas a surprise, that the stumbling block in this field is not the production of antibodies (there are more than 20on the market and hundreds in clinical trials), but rather the lack of robust injection formulations suitable todeliver fragile antibodies to the targeted site in vivo and able to resist rapid degradation upon storage or in theform of stock solutions. This project addresses these key issues by proposing means to employ finely designedamphiphilic macromolecules to rescue antibodies against loss of activity due to aggregation during refolding, tosolubilize them in their aqueous formulations until administration, and to prolong their lifetime in-vivo. Thesuccessful outcome of this project would remove one of the roadblocks towards availability of affordableantibody therapies and open up a new lucrative market to Supratek Pharma Inc., the industrial partner in thisapplication.The project brings together a Canadian academic laboratory that excels in the preparation of amphiphilicbiocompatible macromolecules, a Canadian company specializing in oncological drug delivery systems andtwo French laboratories, which are leaders in the biophysics of proteins/polymer complexes and the productionand of engineered antibody fragments for oncological therapies.